Sir Harpal Kumar,
MA, MEng, MBA, DSc, FMedSci
Head, Johnson & Johnson Innovation, Europe, Middle East, and Africa EMEA - Located at the Innovation Center in London.
Harpal is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Center in London.
He oversees a portfolio of co-investments and collaborations across the region and works to grow the Innovation Center’s networks within the EMEA innovation community – which includes working, and building relationships with academia, venture capital, entrepreneurs, NGOs, and governmental organisations.
Before joining Johnson & Johnson Innovation, Harpal’s career has been largely focused on improving healthcare outcomes through innovation. He spent 15 years with Cancer Research UK (CRUK) and served as the organisation’s Chief Executive from April 2007 until June 2018. Prior to this, he was Chief Operating Officer & Executive Director of Development at CRUK and served as Chief Executive of Cancer Research Technology (a subsidiary of CRUK).
Harpal also served as CEO of The Papworth Trust, which focuses on pioneering rehabilitation services for people with acquired and congenital disabilities. He left this role in 1997 to become founding CEO of Nexan Group, a venture capital-backed medical device company, creating and marketing novel cardio-respiratory monitoring technologies to reduce premature mortality in patients with congestive heart failure.
Harpal was Chair of the Taskforce and author of “Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020”, published in summer 2015. He is a Non-Executive Board member of UK Research & Innovation (UKRI) and the Senior Independent Director of Innovate UK.
Harpal Kumar gained a Masters in Chemical Engineering from the University of Cambridge, and an MBA as a Baker Scholar from Harvard Business School. He has been awarded Honorary Doctorates from the Universities of Manchester, Newcastle and Glasgow and the Institute of Cancer Research and he is a Fellow of The Academy of Medical Sciences. In 2016, he was knighted by Her Majesty Queen Elizabeth II for services to cancer research.